Winston-Salem, NC, Dec. 11, 2017 -- Inmar today announced that it has acquired RASMAS from Noblis Inc., a Reston, Va. based nonprofit science, technology and strategy organization. RASMAS is a web-based subscription service that provides comprehensive notification, distribution, organization and management of product alerts and recalls throughout the healthcare industry.
|
|||
Inmar, a leading provider of recall and product withdrawal services for both pharmaceutical and consumer goods in the U.S. and Canada, has served as the exclusive reseller of RASMAS on behalf of Noblis, Inc. for the past eight years. RASMAS helps its pharmacy clients reduce alert processing time by up to 80 percent - decreasing patient exposure to potentially harmful products. The RASMAS system automatically notifies users when they are affected by recalls by comparing purchase history information with each notification released to increase efficiency and enable products to be removed from shelves faster.
This acquisition, along with that of MedEx and EXP Pharmaceutical Services, further positions Inmar as a powerful ally for healthcare organizations. The MedEx suite of products is designed to automate preparation of medications and track, secure, distribute and confirm medication deliveries in health systems. EXP’s core business of pharmaceutical returns and recalls enabled Inmar to extend its pharmacy financial management services into the hospital market, where EXP had developed a strong presence.
“Speed, accuracy and agility are critical in today’s marketplace – these are the tools that deliver consumer value whether in healthcare, consumer goods, or government. Response times are expected to be in real time,” says Inmar Chairman and CEO David Mounts. “RASMAS’ use of data and artificial intelligence, combined with Inmar’s data, innovation and real time reach, have implications that extend far beyond the current application.”
“Noblis is proud of the impact we’ve made on patient safety through the development of RASMAS,” said Amr ElSawy, Noblis President and CEO. “Inmar has a deep understanding and appreciation of RASMAS and the value it provides to its customers and to patients. We are pleased to know that this important service will continue to grow and evolve as part of their services.”
Financial details associated with the transaction were not disclosed.
# # #
ABOUT INMAR
Anyone who has redeemed a coupon, filled a prescription or returned a product, has touched Inmar. We apply technology and data science to improve outcomes for consumers and those who serve them. As a trusted intermediary for over 35 years, we have unmatched access to billions of consumer and business transactions in real time. Our analytics, platforms and services enable engagement with shoppers and patients, and optimize results. For more information about Inmar’s products and services, please contact (866) 440-6917 or visit www.inmar.com.
ABOUT NOBLIS
Noblis, Inc. is a nonprofit science, technology, and strategy organization that brings the best of scientific thought, management, and engineering expertise in an environment of independence and objectivity. We work with a wide range of government and industry clients in the areas of national security and intelligence, transportation and telecommunications, citizen services, environmental sustainability, and health. Together with our wholly owned subsidiaries, Noblis ESI and Noblis NSP, we tackle the nation’s toughest problems and support our clients’ most critical missions. To learn more visit www.noblis.org.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/f4dd0a1d-0c35-4de8-970f-186454831cae
Sharon Joyner-Payne Inmar, Inc. (336) 631-7663 [email protected]


Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 



